| Identification | Back Directory | [Name]
RUBOXISTAURIN HYDROCHLORIDE | [CAS]
169939-93-9 | [Synonyms]
Ruboxistaurin HCl
Ruboxistaurin(LY333531HCl)
Ruboxistaurin Hydrochloride
LY 333531 hydrochloride - Ruboxistaurin
(9S)-9-[(DiMethylaMino)Methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-DiMethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione Hydrochloride
(S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione monohydrochloride | [Molecular Formula]
C28H29ClN4O3 | [MDL Number]
MFCD00940226 | [MOL File]
169939-93-9.mol | [Molecular Weight]
505.01 |
| Chemical Properties | Back Directory | [alpha ]
D25 -28.7° (c = 1.0 in ethanol) | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO: soluble10mg/mL, clear | [form ]
powder | [color ]
orange-red | [InChIKey]
NYQIEYDJYFVLPO-QAYAHANANA-N | [SMILES]
O=C1NC(=O)C2C3=CN(CCO[C@]([H])(CN(C)C)CCN4C5=CC=CC=C5C(=C4)C1=2)C1=CC=CC=C31.Cl |&1:12,r| |
| Hazard Information | Back Directory | [Description]
LY333531 is an inhibitor of PKCβ (IC50s = 4.7 and 5.9 nM for PKCβ1 and PKCβ2, respectively). It is selective for PKCβ1 and PKCβ2 over PKCα, -γ, -δ, -ε, -ζ, and -η (IC50s = 360, 300, 250, >100,000, and 52 nM, respectively). LY333531 also inhibits glycogen synthase kinase 3β (GSK3β; IC50 = 39.4 nM). It inhibits neutrophil extracellular trap (NET) formation induced by phorbol 12-myristate 13-acetate (PMA; ) in primary human neutrophils when used at a concentration of 1 μM. LY333531 increases the mechanical nociceptive threshold in a rat model of diabetic hyperalgesia induced by streptozotocin (STZ; ). | [Uses]
A protein kinase C (PKC) β inhibitor, exhibits significant anti-angiogenic activity that reduces the response of vascular endothelial cells to stimulation by vascular endothelial growth factor (VEGF). It is used in treatment of diabetic microvascular comp | [Uses]
Ruboxistaurin is a protein kinase C (PKC) β inhibitor, exhibits significant anti-angiogenic activity that reduces the response of vascular endothelial cells to stimulation by vascular endothelial grow
th factor (VEGF). Ruboxistaurin is used in treatment of diabetic microvascular complications. | [in vivo]
Ruboxistaurin (1 mg/kg; 8 weeks) markedly reduces GEC apoptosis as well as swiprosin-1 upregulation, and ameliorates renal glomerular injury in the diabetic mice. Ruboxistaurin also potently attenuates the expression of PARP, cleaved-caspase9, cleaved-caspase3, and the Bax/Bcl-2 ratio, in diabetic mice[3]. Ruboxistaurin (0.1, 1.0, or 10.0 mg/kg; p.o.) dramatically reduces the number of leukocytes trapped in the retinal microcirculation of diabetic rats[4]. | [IC 50]
PKCβI: 4.7 nM (IC50); PKCβII: 5.9 nM (IC50); PKCη: 52 nM (IC50); PKCδ: 250 nM (IC50); PKCγ: 300 nM (IC50); PKCα: 360 nM (IC50); PKCε: 600 nM (IC50) | [References]
[1] MICHAEL R. JIROUSEK. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase Cβ[J]. Journal of Medicinal Chemistry, 1996, 39 14: 2664-2671. DOI: 10.1021/jm950588y
[2] PATRICIA A. VIGNAUX. Machine Learning for Discovery of GSK3β Inhibitors[J]. ACS Omega, 2020, 5 41: 26551-26561. DOI: 10.1021/acsomega.0c03302
[3] ROBERT D GRAY. Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps.[J]. Journal of Inflammation-London, 2013, 10 1: 12. DOI: 10.1186/1476-9255-10-12
[4] HYOH KIM. Protein kinase Cbeta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons.[J]. Diabetes, 2003, 52 8: 2102-2109. DOI: 10.2337/diabetes.52.8.2102 |
|
| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15061/0_EN.htm |
|